Loading clinical trials...
Loading clinical trials...
Evaluation of Efficacy and Safety of Direct Acting Agents in Hepatitis C Patients
This study is a retrospective study conducted at 36 sites. Planned target patient number is 1000.
Approximately 36 centers will be included in Turkey. Centers will be selected from clinics of infection and clinical microbiology. The inclusion of 1000 patients was targeted. All data will be retrospectively collected from the medical records of the patients. Patient visit is not necessary.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Cerrahpasa Medical Faculty
Istanbul, Turkey (Türkiye)
Start Date
April 9, 2017
Primary Completion Date
December 31, 2018
Completion Date
December 31, 2018
Last Updated
October 1, 2019
2,700
ACTUAL participants
Lead Sponsor
Fehmi Tabak
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions